FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70

Biochemical and Biophysical Research Communications

Volumn 356, Issue 4, 2007, Pages 998-1003

  Wang, Ying ^a   Wang, Sheng Yu ^a   Zhang, Xu Hui ^a   Zhao, Ming ^a   Hou, Chun Mei ^a   Xu, Yuan Ji ^a   Du, Zhi Yan ^a   Yu, Xiao Dan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Acetylation; Apoptosis; Chaperone function; FK228; HDAC inhibitor; Hsp70; Hsp90; Leukemia; SAHA

Indexed keywords

BCR ABL PROTEIN; CHAPERONE; FR 901228; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

ACETYLATION; ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION;

ACETYLATION; ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; K562 CELLS; MOLECULAR CHAPERONES;

EID: 34047097863     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.03.076     Document Type: Article

References (30)

1. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
2. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
3. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
4. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D., Ponder B.A., Kouzarides T., and Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24 (2000) 300-303
5. Liang J., Prouty L., Williams B.J., Dayton M.A., and Blanchard K.L. Acute mixed lineage leukemia with an inv (8) (p11q13) resulting in fusion of the genes for MOZ TIF2. Blood 92 (2002) 2118-2122
6. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92 (2000) 1210-1216
7. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., and Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by Depsipeptide FR901228. J. Natl. Cancer Inst. 94 (2002) 504-513
8. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P., and Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63 (2003) 5126-5135
9. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., and Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 417 (2002) 455-458
10. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., and Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90. J. Biol. Chem. 280 (2005) 26729-26734
11. Bali P., Pranpat M., Swaby R., Fiskus W., Yamaguchi H., Balasis M., Rocha K., Wang H.G., Richon V., and Bhalla K. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 11 (2005) 6382-6389
12. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., and Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18 (2005) 601-607
13. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8 (2002) S55-S61
14. Pratt W.B., and Toft D.O. Regulation of signaling protein function, trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 228 (2003) 111-133
15. Nakajima H., Kim Y.B., Terano H., Yoshida M., and Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241 (1998) 126-133
16. Kawano T., Horiguchi-Yamada J., Iwase S., Akiyama M., Furukawa Y., Kan Y., and Yamada H. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res. 24 (2004) 2705-2712
17. Piekarz R.L., Robey R., Sandor V., Bakke S., Wilson W.H., Dahmoush L., Kingma D.M., Turner M.L., Altemus R., and Bates S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98 (2001) 2865-2868
18. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., Shank R., Tejaswi S.L., Binkley P., Wright J., Chan K.K., and Grever M.R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005) 959-967
19. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E., Shen T., Murphy T., Wickham J., Kanakry C., Lucas D.M., Reed J.C., Grever M.R., and Byrd J.C. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102 (2002) 652-658
20. Sutheesophon K., Nishimura N., Kobayashi Y., Furukawa Y., Kawano M., Itoh K., Kano Y., Ishii H., and Furukawa Y. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J. Cell Physiol. 203 (2005) 387-397
21. Blagosklonny M.V., Robey R., Sackett D.L., Du L., Traganos F., Darzynkiewicz Z., Fojo T., and Bates S.E. Histone deacetylase inhibitors all induces p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. 1 (2002) 937-941
22. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., and Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62 (2002) 4916-4921
23. Marcus A.I., Zhou J., O'Brate A., Hamel E., Wong J., Nivens M., El-Naggar A., Yao T.P., Khuri F.R., and Giannakakou P. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. 65 (2005) 3883-3893
24. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., and Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101 (2003) 3236-3239
25. Fortugno P., Beltrami E., Plescia J., Fontana J., Pradhan D., Marchisio P.C., Sessa W.C., and Altieri D.C. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 100 (2003) 13791-13796
26. Johnson C.A., White D.A., Lavender J.S., O'Neill L.P., and Turner B.M. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J. Biol. Chem. 277 (2002) 9590-9597
27. Huang H.C., Liu Y.C., Liu S.H., Tzang B.S., and Lee W.C. Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci. 70 (2002) 1763-1775
28. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., and Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
29. Ren R. Mechanisms of Bcr-Abl in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5 (2005) 172-183
30. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., Holloway A.J., and Johnstone R.W. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102 (2005) 3697-3702